Pharmacology of neuropeptide Y receptor antagonists. Focus on cardiovascular functions.

作者: Rickard E Malmström

DOI: 10.1016/S0014-2999(02)01889-7

关键词: NeuropeptideMechanism of actionNeurotransmitterInternal medicineBiologyPharmacologyNeuropeptide Y receptorNeuroscienceEndocrinologyReceptorPeptide hormoneSympathetic nervous systemNeuropeptide FF receptor

摘要: Neuropeptide Y is one of the most abundant mammalian neuropeptides identified to date. The possible actions neuropeptide Y, that co-localized and released with noradrenaline, as a sympathetic co-transmitter has attracted much attention during last decade. In recent years, several non-peptide antagonists high subtype selectivity for receptors have been introduced. With them, status transmitter established, so profound cardiovascular effects mediated by Y(1) Y(2) receptors. Significant release occurs especially upon stronger activation, data suggest importance seems enhanced in stress-related disorders. true significance thus started unfold, owing presence first generation selective receptor antagonists. This review concerns pharmacology these agents, what we learnt from might find out future.

参考文章(142)
Klaus Rudolf, Wolfgang Eberlein, Wolfhard Engel, Annette G. Beck-Sickinger, Helmut Wittneben, Heike A. Wieland, Henri N. Doods, BIBP 3226, a potent and selective neuropeptide Y Y1-receptor antagonist. Structure-activity studies and localization of the human Y1 receptor binding site Neuropeptide Y and Drug Development. pp. 175- 190 ,(1997) , 10.1016/B978-012304990-2/50010-X
Rickard E. Malmström, Jan M. Lundberg, Neuropeptide y in sympathetic nerves — evidence for Y1 receptor mediated vascular control Neuropeptide Y and Drug Development. pp. 41- 55 ,(1997) , 10.1016/B978-012304990-2/50004-4
Claudine Serradeil-Le Gal, SR 120819A or the first Generation of orally active Y1-receptor antagonists Neuropeptide Y and Drug Development. pp. 157- 174 ,(1997) , 10.1016/B978-012304990-2/50009-3
Dan Larhammar, Extraordinary structural diversity of NPY-family receptors Neuropeptide Y and Drug Development. pp. 87- 105 ,(1997) , 10.1016/B978-012304990-2/50006-8
Graham S. Poindexter, Karen Leboulluec, Jeffrey W. Noonon, Graham Johnson, Marc Bruce, Dihydropyridine NPY antagonists ,(1996)
Rickard E. Malmström, Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control. Acta Physiologica Scandinavica. ,vol. 636, pp. 1- 55 ,(1997)
L. Kaijser, J. Pernow, B. Berglund, J. Grubbstrom, J. M. Lundberg, Neuropeptide Y release from human heart is enhanced during prolonged exercise in hypoxia Journal of Applied Physiology. ,vol. 76, pp. 1346- 1349 ,(1994) , 10.1152/JAPPL.1994.76.3.1346
Michael G. Ziegler, Brian Kennedy, Gregory H. Shen, Neuropeptide Y-Mediated Pressor Responses Following High-Frequency Stimulation of the Rat Sympathetic Nervous System Journal of Pharmacology and Experimental Therapeutics. ,vol. 281, pp. 291- 296 ,(1997)
Annette Beck-Sickinger, Remi Quirion, Dan Larhammar, Henri N. Doods, Herbert Herzog, Thue Schwartz, Helen Cox, Thomas Westfall, Martin C. Michel, XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors Pharmacological Reviews. ,vol. 50, pp. 143- 150 ,(1998)